September 18, 2014

8:08 PM | UM171: New Molecule Allows For 10X Increase In Adult Stem Cell Transplants
Investigators have announced discovery of a new molecule, the first of its kind, which allows for the multiplication of stem cells in a unit of cord blood. Umbilical cord blood contains adult stem cells used for transplants aimed at curing a number of blood-related diseases, including leukemia, myeloma and lymphoma. For many patients this therapy comprises a treatment of last resort. read more
8:00 AM | Working life: Richard Coward
Dr Richard Coward is an MRC Senior Clinical Fellow and Head of Research for the School of Clinical Sciences at the University of Bristol. Here he tell us about his […]

September 17, 2014

3:28 PM | Antidepressants Modulate Memory in the Healthy Brain
The mechanism of antidepressant drug response is not well understood.One theory posits antidepressant effects are only seen in those with clinical depression leaving the healthy brain unchanged.In a previous post, I outlined a study demonstrating effects of antidepressants on brain connectivity measures in the healthy brain.A recent fMRI study extends our understanding of the potential mechanisms for antidepressant drugs.CT Cerqueira and colleagues from Brazil studied the effects of the […]

Cerqueira CT, Sato JR, de Almeida JR, Amaro E Jr, Leite CC, Gorenstein C, Gentil V & Busatto GF (2014). Healthy individuals treated with clomipramine: an fMRI study of brain activity during autobiographical recall of emotions., Translational psychiatry, 4 PMID:


September 13, 2014

12:05 AM | Merck Discontinues Tecemotide For Stage III Non-Small Cell Lung Cancer
Merck is discontinuing the clinical development program of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (L-BLP25) as a monotherapy in Stage III non-small cell lung cancer (NSCLC).Tecemotide is an investigational MUC1 antigen-specific cancer immunotherapy that is designed to stimulate the body's immune system to identify and target cells expressing the cell-surface glycoprotein MUC1. MUC1 is expressed in many cancers, including NSCLC, and has multiple roles in tumor […]

September 12, 2014

8:13 PM | Keytruda: FDA Approves Melanoma Drug That Uses Immune System To Fight Cancer
The U.S. Food and Drug Administration has approved Keytruda (pembrolizumab), a new immunotherapy drug to treat advanced melanoma after it was tested on more than 600 patients who had melanoma that had spread throughout their bodies. Because so many of the patients in the early testing showed significant long-lasting responses, the study was continued and the FDA granted the drug “breakthrough therapy” status, allowing it to be fast-tracked for approval. The largest Phase 1 […]

September 10, 2014

12:00 PM | RVX-208 Brings 77% Relative Risk Reduction Of Major Adverse Cardiovascular Events For Diabetes Mellitus Patients
In an oral presentation at the 2014 European Society of Cardiology (ESC) Congress in Barcelona, Dr. Jan Johansson, senior vice president of medical affairs at Resverlogix, disclosed that patients with cardiovascular disease (CVD) arising from atherosclerosis when given RVX-208 had a 55% (p=0.02) relative risk reduction (RRR) in Major Adverse Cardiovascular Events (MACE).read more

September 09, 2014

1:00 PM | Clinical Trials Of SYN-004 In For C. Difficile Infections Upcoming
Positive results from its final preclinical toxicology study of SYN-004 have led Synthetic Biologics to get ready for clinical trials of the anti-infective, second-generation product candidate for Clostridium difficile (C. difficile). Synthetic Biologics is in the final stages of preparing its SYN-004 IND application for submission to the FDA, with the expectation of initiating Phase Ia and Ib clinical trials in the fourth quarter of 2014, and a Phase II efficacy study in the first half of […]

September 08, 2014

3:30 PM | Fast Track Designation For Motolimod Immunotherapy In Ovarian Cancer
In 2014, there will be an estimated 22,240 new cases of ovarian cancer in the United States and over 40,000 new cases in the European Union. Ovarian cancer is one of the most lethal gynecologic cancers. Women with recurrent or persistent ovarian cancer recur within 6-12 months of completion with a platinum-containing regimen and there remains a high unmet need for improved treatment more
1:01 PM | Randomized Phase II Clinical Trial Of Pracinostat Set For Front Line Myelodysplastic Syndrome
Enrollment in a randomized Phase II clinical trial of Pracinostat in combination with azacitidine in patients with previously untreated intermediate-2 or high-risk myelodysplastic syndrome (MDS) has been completed. The multi-center, placebo-controlled, double-blind study enrolled a total of 108 patients with a one-to-one randomization. The Company plans to unblind the study approximately six months after the last patient was enrolled and report topline data in Q1 more
1:00 AM | New Antifungal Isavuconazole As Effective As Voriconazole With Fewer Adverse Events
A newly developed antifungal named isavuconazole is as effective as voriconazole against invasive mold disease in cancer patients with less adverse effects, according to phase 3 clinical more

September 02, 2014

5:00 PM | Sickle Cell Is Still A Killer But This 50 Cent Test Could Change That
A simple solution to a persistent problem. Credit: Ashok A. KumarBy Ashok A. Kumar, Harvard UniversityEvery year, 300,000 children are born with sickle-cell disease, primarily in Africa and India. It is a genetic disorder that causes some blood cells to become abnormally shaped. The result is that those who suffer from it have a shorter lifespan. read more
3:44 PM | MITOCARE: TRO40303 Hopes Dashed For Preventing Reperfusion Injury After Heart Attack
 Reperfusion injury prevention isn't possible just yet. The administration of an experimental agent known as TRO40303 to patients who have had a heart attack, with the hope of preventing tissue damage when impaired blood flow is corrected (reperfusion), was disappointingly ineffective, according to results of a European study of patients with acute ST-elevation myocardial infarction (STEMI) presented today at ESC Congress 2014 and published in the European Heart more

September 01, 2014

12:28 PM | Tracking the Daily Microbiome
Humans are essentially 90% bacteria. These bacteria pepper our skin and hang out in our digestive tracts, helping to break down complex carbohydrates and keeping bad bugs in check. We know how the human microbiome (our collection of bacteria) gets … Continue reading →

David LA, Materna AC, Friedman J, Campos-Baptista MI, Blackburn MC, Perrotta A, Erdman SE & Alm EJ (2014). Host lifestyle affects human microbiota on daily timescales., Genome biology, 15 (7) PMID:

13 Results